NEW YORK (AP) — Boehringer Ingelheim Pharmaceuticals Inc. and Pfizer Inc. said Thursday the Food and Drug Administration approved Spiriva HandiHaler as a treatment for reducing symptoms and difficulty breathing because of chronic obstructive pulmonary disease. The inhalable drug is already approved as a once-daily maintenance treatment for breathing problems associated with the condition, also called COPD, which includes chronic bronchitis and emphysema. Symptoms associated with the condition include wheezing and difficulty breathing.
Related Articles Read More >

The need for a data-driven culture in life sciences: What you don’t know can hurt you

The economics behind the Adderall shortage: Why low prices lead to scarcity
The battle of the bulge: Semaglutide and tirzapatide could be new weight-loss warriors
